In addition, blocking leptin signaling using a full-length leptin receptor (ObR) antagonist also reduced mammosphere formation indicating a potential therapeutic target to block stromal-tumor interactions driving breast CSC-mediated disease progression [206]. Here, LEP is linked to neoplasm.